Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D Haens G; IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis.
Volkers A, et al. Among authors: dijkstra g.
Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 2022 Jul 23.
Aliment Pharmacol Ther. 2022.
PMID: 35869807
Free PMC article.